Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)

The summary for the Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required): The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials. In addition, this NOFO seeks to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained over time to enhance effectiveness and generalizability. The NOFO will support studies designed to enhance the rigor of RAPID clinical trial design, which will ultimately increase the interpretability of the data and the generalizability of the results.

Federal Grant Title:	Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-MH-27-135
Type of Funding:	Grant
CFDA Numbers:	93.242, 93.279
CFDA Descriptions:	Information not provided
Current Application Deadline:	October 11th, 2026
Original Application Deadline:	October 11th, 2026
Posted Date:	April 29th, 2026
Creation Date:	April 29th, 2026
Archive Date:	December 10th, 2026
Total Program Funding:	$5,500,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:	5
Cost Sharing or Matching:	No
Last Updated:	April 29th, 2026

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Grant Announcement Contact: Division of Translational Research
[email protected]
[email protected]
Similar Government Grants: • Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Data Processing...; • Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowe...; • Optimizing Treatment Strategies for Adult Attention-Deficit Hyperactivity Disorder (ADHD) ...; • National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of...; • National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of...; • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...; • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...; • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health: • The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Lab...; • The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations ...; • NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed); • Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Data Processing...; • NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)